RESEARCH PAPER
Analysis of clinical trials in provincial capitals in Poland
 
More details
Hide details
1
Zakład Biologii i Zaburzeń Lipidowych, Uniwersytet Medyczny im. Karola Marcinkowskiego, Polska
CORRESPONDING AUTHOR
Mikolaj Bartoszkiewicz   

Zakład Biologii i Zaburzeń Lipidowych, Uniwersytet Medyczny im. Karola Marcinkowskiego, Rokietnicka 8, 60-806, Poznań, Polska
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and Objectives:
Clinical trials are an opportunity for patients to access innovative therapies that are often unavailable in the national healthcare system. The aim of the study is to compare the number of clinical trials in porovincial cities in Poland, with consideration of the fields of medicine. The comparison concerns the total number of clinical experiments with the number of clinical trials per 25,000 residents of the provincial cities.

Material and methods:
The www.clinicaltrials.gov database, a database of clinical trials financed from private and public funds carried out worldwide, was used to analyze the number of clinical trials. Statistical analysis was performed using the software STATISTICA version 13.3.

Results:
Among the provincial cities, the largest number of clinical trials were conducted in Warsaw – 702, followed by Kraków – 576, and Łódź – 487. Considering the number of clinical trials per 25,000 residents of the provincial cities, the largest number of trials without division into therapeutic fields were carried out in Lublin – 28.64, followed by Białystok – 25.73 and Olsztyn – 24.13.

Conclusions:
Taking into account the number of inhabitants of the individual provincial cities and the number of clinical trials conducted in a given city, the results show that the largest number of medical experiments? clinical trials does not always correlate with the largest number of trials per 25,000 residents.

 
REFERENCES (25)
1.
Friedman LM, Furberg CD, DeMet DL, Reboussin DM, Grange CB. Fundamentals of Clinical Trials. Cham: Springer; 2015. ISBN 978-3-319-18538-5.
 
2.
Unger JM, Cook E, Tai E, Bleyer A. Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book. doi: 10.14694/EDBK_156686.
 
3.
Brodniewicz T. Badania kliniczne. Warszawa: CeDeWu; 2015. ISBN 978-83-7556-715-1.
 
4.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA; 2018, Vol. 68, No. 6, November/December, pp. 394–424.
 
5.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA; 2018, Vol. 68, No. 6, November/December, pp. 394–425.
 
6.
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004, Jun 9; 291(22): 2720–6.
 
7.
Clinicaltrials.gov (access: 1.10.2019).
 
8.
Leiter A, Diefenbach MA, Doucette J, Oh WK, Galsky MD. Clinical trial awareness: Changes over time and sociodemographic disparities, Clin Trials. 2015 Jun; 12(3): 215–223. doi: 10.1177/1740774515571917.
 
9.
Huang GD, Altemose JK, O’Leary TJ. Public access to clinical trials: Lessons from an organizational implementation of policy. Contemporary Clinical Trials. 2017, Vol. 57, June, pp. 87–89.
 
10.
Calvo G, McMurray JJ, Granger CB, Alonso-Garcia A, Armstrong P, Flather M, Gomez-Outes A, Pocock S, Stockbridge N, Svensson A, Van de Werf F. Large streamlined trials in cardiovascular disease. Eur Heart J. 2014; 35: 544–548.
 
11.
European Commission. Assessment of the functioning of the “Clinical Trials Directive” 2001/20EC public consultation paper. http://ec.europa.eu/health/fil..., … (access: 05.10.2019).
 
12.
Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, Fraass U, Friede T, Hannachi H, Janmohamed S, Kreuzer J, Landray M, Lautsch D, Le Floch C, Mol P, Naci H, Samani N, Svensson A, Thorstensen C, Tijssen J, Vandzhura V, Zalewski A, Kirchhof P. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Roundtable of the European Society of Cardiology. Eur Heart J. 2016; 37: 747–754.
 
13.
Komajda M, Coats A, Cowie MR, Jackson N, Svensson A, Vardas P. Championing cardiovascular health innovation in Europe. Eur Heart J. 2013; 34: 2630–2635.
 
14.
Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013; 31(5): 536–542. doi: 10.1200/JCO.2012.45.4553.
 
15.
Grunfeld E, Zitzelsberger L, Coristine M, Aspelund F. Barriers and facilitators to enrollment in cancer clinical trials. Cancer. 2002; 95(7): 1577–1583. doi: 10.1002/cncr.10862.
 
16.
Carey M, Boyes AW, Smits R, Bryant J, Waller A, Olver I. Access to clinical trials among oncology patients: results of a cross sectional survey, J Clin Oncol. 2013, Feb 10; 31(5): 536–542. doi: 10.1200/JCO.2012.45.4553.
 
17.
Doroshow JH. Timely completion of scientifically rigorous cancer clinical trials: an unfulfilled priority. J Clin Oncol. 2013; 31(27): 3312–3314. doi: 10.1200/JCO.2013.51.3192.
 
18.
Ministerstwo Zdrowia, https://www.gov.pl/web/zdrowie... [(dostęp: 13.02.2020).].
 
19.
Biuletyn Rocznych Produktów Leczniczych, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, 2019, http://urpl.gov.pl/pl/biuletyn... [(dostęp: 13.02.2020).].
 
20.
Raport Badania kliniczne w Polsce -– Główne wyzwania, wyd. PriceWatherHouseCoopers, 2010. Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials., J Clin Oncol. 2003, Mar 1; 21(5): 830–835. doi: 10.1200/JCO.2003.02.105.
 
21.
Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials., J Clin Oncol. 2003, Mar 1; 21(5): 830–835. doi: 10.1200/JCO.2003.02.105.
 
22.
Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol. 2001; 19: 1728–1733.
 
23.
Klabunde CN, Springer BC, Butler B, et al. Factors influencing enrollment in clinical trials for cancer treatment. South Med J. 1999; 92: 1189–1193.
 
24.
Javid SH, Unger JM, Gralow JR, et al. A prospective analysis of the influence of older age on physician and patient decision making when considering enrollment to breast cancer clinical trials (SWOG S0316) Oncologist. 2012; 17: 1180–1190.
 
25.
Unger J, Unger M, Dawn L, Hershman DL, Kathy S, Albain KS, Carol M, Moinpour CM, Judith A, Petersen JA, Kenda Burg K, Crowley JJ. Patient Income Level and Cancer Clinical Trial Participation, J Clin Oncol. 2013, Feb 10; 31(5): 536–542. doi: 10.1200/JCO.2012.45.4553.
 
eISSN:2084-4905
ISSN:2083-4543